Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | EVP, General Counsel | June 22, 2020 | June 23, 2020 |
| Solid Biosciences Inc.SLDB · Entity 4915 | Chief Operating Officer | January 29, 2026 | April 21, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | SVP & Chief Legal Officer | February 02, 2012 | February 06, 2012 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sarepta Therapeutics, Inc.
Report date June 22, 2020 · Filed June 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,871 |
Ending reported balance
After 2020-06-22 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2020-06-22 · Exercise / conversion · Acquired 1,280 · Balance 33,151 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Row 2 · 2020-06-22 · Exercise / conversion · Acquired 1,858 · Balance 35,009 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Row 3 · 2020-06-22 · Exercise / conversion · Acquired 56,984 · Balance 91,993 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Row 4 · 2020-06-22 · Exercise / conversion · Acquired 45,000 · Balance 136,993 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Row 5 · 2020-06-22 · Sale · Disposed 6,009 · Balance 130,984 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. F2: The shares were sold in transactions at prices ranging from $168.04 to $169.0399, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 6 · 2020-06-22 · Sale · Disposed 8,086 · Balance 122,898 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. F3: The shares were sold in transactions at prices ranging from $169.09 to $170.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 7 · 2020-06-22 · Sale · Disposed 35,757 · Balance 87,141 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. F4: The shares were sold in transactions at prices ranging from $170.09 to $171.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 8 · 2020-06-22 · Sale · Disposed 55,270 · Balance 31,871 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. F5: The shares were sold in transactions at prices ranging from $171.09 to $172.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.71 · Expires 2026-02-28 | Direct | 0 |
Reported balance
After 2020-06-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-06-22 · Exercise / conversion · Disposed 1,280 · Balance 0 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.71 · Expires 2026-02-28 | Direct | 0 |
Reported balance
After 2020-06-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-06-22 · Exercise / conversion · Disposed 1,858 · Balance 0 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.85 · Expires 2022-11-05 | Direct | 0 |
Reported balance
After 2020-06-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-06-22 · Exercise / conversion · Disposed 56,984 · Balance 0 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.03 · Expires 2024-02-28 | Direct | 7,708 |
Reported balance
After 2020-06-22 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-06-22 · Exercise / conversion · Disposed 45,000 · Balance 7,708 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.
F2: The shares were sold in transactions at prices ranging from $168.04 to $169.0399, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3: The shares were sold in transactions at prices ranging from $169.09 to $170.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4: The shares were sold in transactions at prices ranging from $170.09 to $171.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5: The shares were sold in transactions at prices ranging from $171.09 to $172.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Solid Biosciences Inc.
Report date January 29, 2026 · Filed April 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 79,341 |
Reported balance
After 2026-01-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-29 · Grant · Acquired 79,341 · Balance 79,341 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F2: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
F2: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.
VERTEX PHARMACEUTICALS INC / MA
Report date February 02, 2012 · Filed February 06, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,437 |
Reported balance
After 2012-02-02 transaction · row 1
1 source rowRow 1 · 2012-02-02 · Grant · Acquired 10,166 · Balance 19,437 F1: Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $37.86 · Expires 2022-02-01 | Direct | 68,750 |
Reported balance
After 2012-02-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2012-02-02 · Grant · Acquired 68,750 · Balance 68,750 F2: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 266 |
Reported balance
Holding disclosure · report date 2012-02-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 266 |
Filing footnotes · ownership attribution and instrument terms
F1: Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection.
F2: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 22, 2019 Filed Nov 27, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 7,900 | $0.00 Strike: $23.85 | $0.00 |
DisclosureSEC source: 0001209191-19-058217 · doc4.xml · derivative · entry 18 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,118 Underlying: Common Stock · 7,900 shares Expires 2022-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2019 Filed Nov 27, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 5,590 | $0.00 Strike: $13.90 | $0.00 |
DisclosureSEC source: 0001209191-19-058217 · doc4.xml · derivative · entry 17 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,590 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2019 Filed Nov 27, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 52 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001209191-19-058217 · doc4.xml · derivative · entry 16 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18 Underlying: Common Stock · 52 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2019 Filed Nov 27, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 2,440 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001209191-19-058217 · doc4.xml · derivative · entry 15 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,470 Underlying: Common Stock · 2,440 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2019 Filed Nov 27, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 8,580 | $0.00 Strike: $13.90 | $0.00 |
DisclosureSEC source: 0001209191-19-058217 · doc4.xml · derivative · entry 14 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,579 Underlying: Common Stock · 8,580 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| November 22, 2019 Filed Nov 27, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 4,025 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001209191-19-058217 · doc4.xml · derivative · entry 13 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,858 Underlying: Common Stock · 4,025 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| November 22, 2019 Filed Nov 27, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 5,685 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001209191-19-058217 · doc4.xml · derivative · entry 12 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,280 Underlying: Common Stock · 5,685 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| November 22, 2019 Filed Nov 27, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 2,804 | $107.02 | $300,084.08 |
DisclosureSEC source: 0001209191-19-058217 · doc4.xml · nonDerivative · entry 11 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,171 F2 · kind: Represents shares of Common Stock owned by the reporting person that were delivered to the Company to pay the aggregate exercise price with respect to the option exercises reported in rows 4-7 in Table II of this Form 4 filing. Read SEC document |
| November 22, 2019 Filed Nov 27, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 7,900 | $23.85 | $188,415.00 |
DisclosureSEC source: 0001209191-19-058217 · doc4.xml · nonDerivative · entry 10 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2019 Filed Nov 27, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 5,590 | $13.90 | $77,701.00 |
DisclosureSEC source: 0001209191-19-058217 · doc4.xml · nonDerivative · entry 9 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2019 Filed Nov 27, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 52 | $13.71 | $712.92 |
DisclosureSEC source: 0001209191-19-058217 · doc4.xml · nonDerivative · entry 8 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2019 Filed Nov 27, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 2,440 | $13.71 | $33,452.40 |
DisclosureSEC source: 0001209191-19-058217 · doc4.xml · nonDerivative · entry 7 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2019 Filed Nov 27, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 2,957 | $105.00 | $310,485.00 |
DisclosureSEC source: 0001209191-19-058217 · doc4.xml · nonDerivative · entry 6 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,993 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| November 22, 2019 Filed Nov 27, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 3,753 | $105.00 | $394,065.00 |
DisclosureSEC source: 0001209191-19-058217 · doc4.xml · nonDerivative · entry 5 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,950 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| November 22, 2019 Filed Nov 27, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 18,290 | $105.00 | $1,920,450.00 |
DisclosureSEC source: 0001209191-19-058217 · doc4.xml · nonDerivative · entry 4 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,703 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| November 22, 2019 Filed Nov 27, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 8,580 | $13.90 | $119,262.00 |
DisclosureSEC source: 0001209191-19-058217 · doc4.xml · nonDerivative · entry 3 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| November 22, 2019 Filed Nov 27, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 4,025 | $13.71 | $55,182.75 |
DisclosureSEC source: 0001209191-19-058217 · doc4.xml · nonDerivative · entry 2 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,413 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| November 22, 2019 Filed Nov 27, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 5,685 | $13.71 | $77,941.35 |
DisclosureSEC source: 0001209191-19-058217 · doc4.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| March 28, 2019 Filed Mar 30, 2019 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 2,362 | $118.68 | $280,322.16 |
DisclosureSEC source: 0001209191-19-021876 · doc4.xml · nonDerivative · entry 2 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,703 F2 · price: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of performance-based restricted stock units. Read SEC document |
| March 28, 2019 Filed Mar 30, 2019 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 5,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021876 · doc4.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,065 F1 · price: The transaction reflects the vesting of previously granted performance-based restricted stock units. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 01:07 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 45,000 | $0.00 Strike: $145.48 | $0.00 |
DisclosureSEC source: 0001209191-19-016040 · doc4.xml · derivative · entry 2 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-03-04 F2 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 01:07 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Disposition to issuerCommon Stock | 3,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016040 · doc4.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,746 F1 · shares: Forfeiture of 3,825 shares of restricted stock due to performance goal not met. Read SEC document |
| February 01, 2019 Filed Feb 2, 2019 01:25 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 16,827 | $23.85 Strike: $23.85 | $401,323.95 |
DisclosureSEC source: 0001209191-19-006630 · doc4.xml · derivative · entry 7 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,405 Underlying: Common Stock · 16,827 shares Expires 2022-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| February 01, 2019 Filed Feb 2, 2019 01:25 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 1,548 | $13.71 Strike: $13.71 | $21,223.08 |
DisclosureSEC source: 0001209191-19-006630 · doc4.xml · derivative · entry 6 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,883 Underlying: Common Stock · 1,548 shares Expires 2025-09-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| February 01, 2019 Filed Feb 2, 2019 01:25 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 3,125 | $13.71 Strike: $13.71 | $42,843.75 |
DisclosureSEC source: 0001209191-19-006630 · doc4.xml · derivative · entry 5 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,965 Underlying: Common Stock · 3,125 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| February 01, 2019 Filed Feb 2, 2019 01:25 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 30,000 | $140.00 | $4,200,000.00 |
DisclosureSEC source: 0001209191-19-006630 · doc4.xml · nonDerivative · entry 4 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,571 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| February 01, 2019 Filed Feb 2, 2019 01:25 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 16,827 | $23.85 | $401,323.95 |
DisclosureSEC source: 0001209191-19-006630 · doc4.xml · nonDerivative · entry 3 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| February 01, 2019 Filed Feb 2, 2019 01:25 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 1,548 | $13.71 | $21,223.08 |
DisclosureSEC source: 0001209191-19-006630 · doc4.xml · nonDerivative · entry 2 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| February 01, 2019 Filed Feb 2, 2019 01:25 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 3,125 | $13.71 | $42,843.75 |
DisclosureSEC source: 0001209191-19-006630 · doc4.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| August 08, 2018 Filed Aug 8, 2018 22:14 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 6,800 | $121.02 | $822,936.00 |
DisclosureSEC source: 0001209191-18-045905 · doc4.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,071 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of performance-based restricted stock award granted on September 19, 2016. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 22:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 37,848 | $13.90 Strike: $13.90 | $526,087.20 |
DisclosureSEC source: 0001209191-18-042890 · doc4.xml · derivative · entry 9 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,159 Underlying: Common Stock · 37,848 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 15, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 22:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 9,056 | $13.71 Strike: $13.71 | $124,157.76 |
DisclosureSEC source: 0001209191-18-042890 · doc4.xml · derivative · entry 8 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,090 Underlying: Common Stock · 9,056 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 15, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 22:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 3,096 | $13.71 Strike: $13.71 | $42,446.16 |
DisclosureSEC source: 0001209191-18-042890 · doc4.xml · derivative · entry 7 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,431 Underlying: Common Stock · 3,096 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 15, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 22:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 37,848 | $136.46 | $5,164,738.08 |
DisclosureSEC source: 0001209191-18-042890 · doc4.xml · nonDerivative · entry 6 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,871 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 15, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 22:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 37,848 | $13.90 | $526,087.20 |
DisclosureSEC source: 0001209191-18-042890 · doc4.xml · nonDerivative · entry 5 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 15, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 22:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 9,056 | $136.46 | $1,235,781.76 |
DisclosureSEC source: 0001209191-18-042890 · doc4.xml · nonDerivative · entry 4 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,871 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 15, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 22:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 9,056 | $13.71 | $124,157.76 |
DisclosureSEC source: 0001209191-18-042890 · doc4.xml · nonDerivative · entry 3 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 15, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 22:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 3,096 | $136.46 | $422,480.16 |
DisclosureSEC source: 0001209191-18-042890 · doc4.xml · nonDerivative · entry 2 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,871 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 15, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 22:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 3,096 | $13.71 | $42,446.16 |
DisclosureSEC source: 0001209191-18-042890 · doc4.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,967 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 15, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| May 22, 2018 Filed May 24, 2018 22:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionRestricted Stock Units · Derivative | 5,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033109 · doc4.xml · derivative · entry 3 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,319 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On March 10, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units, and the second performance criterion was met on May 22, 2018, resulting in vesting of additional 25% of such restricted stock units. F3 · derivative.expiration_date: On March 10, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units, and the second performance criterion was met on May 22, 2018, resulting in vesting of additional 25% of such restricted stock units. Read SEC document |
| May 22, 2018 Filed May 24, 2018 22:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 1,566 | $89.22 | $139,718.52 |
DisclosureSEC source: 0001209191-18-033109 · doc4.xml · nonDerivative · entry 2 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,871 F2 · price: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock units granted on March 10, 2017. Read SEC document |
| May 22, 2018 Filed May 24, 2018 22:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 5,319 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-033109 · doc4.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:12 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 2,074 | $0.00 Strike: $23.85 | $0.00 |
DisclosureSEC source: 0001209191-18-020353 · doc4.xml · derivative · entry 9 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,018 Underlying: Common Stock · 2,074 shares Expires 2022-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:12 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 403 | $0.00 Strike: $13.90 | $0.00 |
DisclosureSEC source: 0001209191-18-020353 · doc4.xml · derivative · entry 8 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,590 Underlying: Common Stock · 403 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:12 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 23 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001209191-18-020353 · doc4.xml · derivative · entry 7 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70 Underlying: Common Stock · 23 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:12 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 609 | $81.22 | $49,462.98 |
DisclosureSEC source: 0001209191-18-020353 · doc4.xml · nonDerivative · entry 6 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,118 F1 · shares: The Reporting Person delivered already-owned shares of Common Stock in payment of the option exercise price. Such an "option swap" enables the exercise and holding of shares of Common Stock by the Reporting Person. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:12 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 2,074 | $23.85 | $49,464.90 |
DisclosureSEC source: 0001209191-18-020353 · doc4.xml · nonDerivative · entry 5 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:12 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 68 | $81.22 | $5,522.96 |
DisclosureSEC source: 0001209191-18-020353 · doc4.xml · nonDerivative · entry 4 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,653 F1 · shares: The Reporting Person delivered already-owned shares of Common Stock in payment of the option exercise price. Such an "option swap" enables the exercise and holding of shares of Common Stock by the Reporting Person. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:12 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 403 | $13.90 | $5,601.70 |
DisclosureSEC source: 0001209191-18-020353 · doc4.xml · nonDerivative · entry 3 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:12 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 3 | $81.22 | $243.66 |
DisclosureSEC source: 0001209191-18-020353 · doc4.xml · nonDerivative · entry 2 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,318 F1 · shares: The Reporting Person delivered already-owned shares of Common Stock in payment of the option exercise price. Such an "option swap" enables the exercise and holding of shares of Common Stock by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.